Treatment of Patients With Anxiety Disorder (0777-022)

Merck Sharp & Dohme LLC270 enrolled

Overview

The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

270

Conditions

Generalized Anxiety Disorder

Interventions

MK0777DRUG

Duration of Treatment: 4 weeks

Comparator: placebo (unspecified)DRUG

Duration of Treatment: 4 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and Female patients ages 18 to 70 Exclusion Criteria: * Women who are breastfeeding or pregnant * Positive result at prestudy on urine drug screen for illicit drugs * History of alcohol or drug abuse

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.